Morgan Dempsey Capital Management LLC Q3 2023 vs. Q4 2023 13F Holdings Comparison
Ava Hoppe | 27 January, 2024
Morgan Dempsey Capital Management LLC is a well-known investment management firm that provides financial services to a wide range of clients. Their quarterly reports, known as 13F filings, provide valuable insights into their investment holdings and any changes that have occurred. In this article, we will analyze the Q3 2023 vs. Q4 2023 13F Holdings Comparison for Morgan Dempsey Capital Management LLC.
Gilead Sciences Inc (GILD)
Gilead Sciences Inc is a biopharmaceutical company that focuses on the research and development of innovative medicines. In the Q3 2023 13F filing, Morgan Dempsey Capital Management LLC held 159,523 shares of Gilead Sciences Inc. However, in the Q4 2023 filing, their holdings decreased to 150,847 shares, representing a 2.2% decrease. The value of their holdings also experienced a slight increase, from $11,954,000 in Q3 to $12,220,000 in Q4.
Exxon Mobil Corp (XOM)
Exxon Mobil Corp is one of the largest publicly traded international oil and gas companies. Morgan Dempsey Capital Management LLC held 128,382 shares of Exxon Mobil Corp in Q3 2023. However, their holdings decreased to 120,900 shares in Q4 2023, representing a significant decrease of 19.9%. The value of their holdings also decreased from $15,095,000 in Q3 to $12,087,000 in Q4.
Phillips 66 (PSX)
Phillips 66 is a diversified energy manufacturing and logistics company. In Q3 2023, Morgan Dempsey Capital Management LLC held 115,989 shares of Phillips 66. However, their holdings decreased to 89,358 shares in Q4 2023, representing a decrease of 14.6%. The value of their holdings also decreased from $13,936,000 in Q3 to $11,897,000 in Q4.
International Business Machines Corp (IBM)
International Business Machines Corp, also known as IBM, is a multinational technology company. In Q3 2023, Morgan Dempsey Capital Management LLC held 74,247 shares of IBM. However, their holdings decreased to 70,439 shares in Q4 2023, representing a decrease of 10.6%. The value of their holdings, however, increased from $10,416,000 in Q3 to $11,520,000 in Q4.
McDonald's Corp (MCD)
McDonald's Corp is a global fast-food restaurant chain. In Q3 2023, Morgan Dempsey Capital Management LLC held 37,875 shares of McDonald's Corp. However, their holdings decreased to 35,928 shares in Q4 2023, representing a decrease of 6.8%. The value of their holdings also increased from $9,977,000 in Q3 to $10,653,000 in Q4.
General Dynamics Corp (GD)
General Dynamics Corp is an aerospace and defense company. In Q3 2023, Morgan Dempsey Capital Management LLC held 42,914 shares of General Dynamics Corp. However, their holdings decreased to 40,777 shares in Q4 2023, representing a decrease of 11.7%. The value of their holdings also increased from $9,482,000 in Q3 to $10,588,000 in Q4.
These are just a few examples of the changes in holdings that occurred between Q3 2023 and Q4 2023 for Morgan Dempsey Capital Management LLC. It is important to note that these holdings and changes are subject to market conditions and investment strategies. Investors should always conduct their own research and analysis before making any investment decisions.
Other Posts
- Arrowgrass Capital Partners' Q3 2019 vs. Q4 2019: A Comprehensive Analysis of 13F Holdings
- Navigating the Winds of Change: A Deep Dive into Northside Capital Management's Investment Shifts
- Navigating the Dental Seas: How MB2 Dental Sailed to Its 700th Practice Milestone
- Bislett Management sheds holdings and maintains core positions in Q3 and Q4 2022 portfolio updates
- Navigating New Horizons: How Vehicle Management Solutions Revved Up Its Market Presence
- Vishria Bird Financial Group, LLC Q1 2023 vs. Q2 2023 13F Holdings Comparison
- Ami Asset Management Corp Q2 2023 vs. Q3 2023 13F Holdings Comparison
- Tracking Providence Capital Advisors' Q3 to Q4 2022 13F Holdings: Which Stocks Have Increased and Decreased?
- Homrich & Berg's Q2 vs. Q3 2021 13F Holdings Comparison: Analysis and Implications for Investors
- Kohlberg Acquires Majority Stake in Worldwide Clinical Trials: A New Era of Growth Begins